Global /Australia /Healthcare /Medical Care Facilities /IIQ

INOVIQ Ltd.

IIQ

• ASX: IIQ • Delayed

0.3250AUD -3%

0.2289 USD

As of 8 June 2026, INOVIQ Ltd. has a market cap of $33.26M USD, ranking #33455 globally and #881 in Australia. It ranks #3022 in the Healthcare sector, and #366 in the Medical Care Facilities industry.

Global Rank

33455

Country Rank

881

Sector Rank

3022

Industry Rank

366

Key Stats

Market Cap

$33.26MUSD

47.16M AUD

Enterprise Value

$23.69MUSD

33.63M AUD

Revenue (TTM)

$1.48MUSD

2.1M AUD

EBITDA (TTM)

-$4.5MUSD

-6.39M AUD

Net Income (TTM)

-$5.1MUSD

-7.24M AUD

PS Ratio

22.4

PB Ratio

2.1

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Medical Care Facilities

CEO

Leearne Hinch open_in_new

Employees

Founded

2016

Website

inoviq.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3%	-1.5%	-2.9%	-8.2%	-2.2%	-14%	-8.2%	-41%	-89%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	IIQ Inoviq Ltd ISIN: AU0000196149 Shares Out.: Shares Outstanding: 140.775M¹ Shares Float: 91.892M² TV: TradingView: ASX: IIQ SA: Stock Analysis: ASX: IIQ YF: Yahoo Finance: IIQ.AX GF: Google Finance: ASX: IIQ BA: Barron's: IIQ MS: Morningstar: XASX: IIQ	0.3250 AUD	TV: TradingView: ASX: IIQ SA: Stock Analysis: ASX: IIQ YF: Yahoo Finance: IIQ.AX GF: Google Finance: ASX: IIQ BA: Barron's: IIQ MS: Morningstar: XASX: IIQ

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About INOVIQ Ltd.

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

Similar Companies

Industry: Medical Care Facilities (Australia)

Name	Market Cap (USD) diff.	PE	Country
Sonic Healthcare Ltd. ASX: SHL	$6.94B 9.85B AUD 21K%	18.0	Australia
Ramsay Health Care Ltd. ASX: RHC	$6.31B 8.95B AUD 19K%	32.8	Australia
Regis Healthcare Ltd. ASX: REG	$1.38B 1.96B AUD 4K%	51.8	Australia
Integral Diagnostics Ltd. ASX: IDX	$575.27M 815.75M AUD 2K%	58.4	Australia
Healius Ltd. ASX: HLS	$263.72M 373.96M AUD 693%	-	Australia
Australian Clinical Labs Ltd. ASX: ACL	$251.44M 356.55M AUD 656%	13.5	Australia

Industry: Medical Care Facilities (Global)

Name	Market Cap (USD) diff.	PE	Country
International Holding Company PJSC ADX: IHC	$232.22B 852.82B AED 698K%	44.1	United Arab Emirates
HCA Healthcare, Inc. NYSE: HCA	$96.73B 291K%	14.9	United States
Fresenius SE & Co. KGaA XETRA: FRE	$26.68B 22.97B EUR 80K%	15.0	Germany
Koninklijke Philips N.V. AMS: PHIA	$25.58B 22.02B EUR 77K%	24.9	Netherlands
Dr. Sulaiman Al Habib Medical Services Group Co. TADAWUL: 4013	$22.46B 84.42B SAR 67K%	35.2	Saudi Arabia
Labcorp Holdings Inc. NYSE: LH	$21.13B 63K%	24.6	United States

chevron_leftBack